RT Journal Article
T1 A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.
A1 Rodriguez-Gallego, Esther
A1 Gomez, Josep
A1 Pacheco, Yolanda M
A1 Peraire, Joaquim
A1 Vilades, Consuelo
A1 Beltran-Debon, Raul
A1 Mallol, Roger
A1 Lopez-Dupla, Miguel
A1 Veloso, Sergi
A1 Alba, Veronica
A1 Blanco, Julia
A1 Cañellas, Nicolau
A1 Rull, Anna
A1 Leal, Manuel
A1 Correig, Xavier
A1 Domingo, Pere
A1 Vidal, Francesc
K1 antiretroviral therapy
K1 biomarkers
K1 HIV-1
K1 metabolomics
K1 poor immune recovery
AB Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir ( We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4 T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
PB Lippincott Williams & Wilkins
YR 2018
FD 2018
LK http://hdl.handle.net/10668/11953
UL http://hdl.handle.net/10668/11953
LA en
NO Rodríguez-Gallego E, Gómez J, Pacheco YM, Peraire J, Viladés C, Beltrán-Debón R, et al.  A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. AIDS. 2018 Mar 13;32(5):565-573.
NO The current work was supported by grants from the Fondo de Investigacion Sanitaria (PI10/02635, PI13/00796, PI13/01912, PI14/01693, PI14/0700, PI14/0063 and PI16/00503) Instituto de Salud Carlos III; Fondos Europeos para el Desarrollo Regional (FEDER); Programa de Suport als Grups de Recerca AGAUR (2014SGR250 and 2009SGR1061); the Gilead Fellowship Program (GLD13/00168 and GLD14/293); the Junta de Andalucía, Consejería de Economía, Innovación, Ciencia y Empleo (Proyecto de Investigación de Excelencia; CTS2593); the Red de Investigación en Sida (RIS) (RD12/0017/0002, RD12/0017/0005, RD12/0017/0014, RD12/0017/0029 and RD16/0025/0006) Instituto de Salud Carlos III, Spain. F.V. and P.D. are supported by a grant from the Programa de Intensificación de Investigadores, Instituto de Salud Carlos III (INT11/240, INT12/282 and INT12/383, INT13/232, INT15/226 and INT15/140). Y.M.P. was supported by the Fondo de Investigación Sanitaria through the ‘Miguel Servet’ program (CPII13/00037) and by the Consejería de Salud y Bienestar Social of Junta de Andalucía through the ‘Nicolás Monardes’ program (C-0010/13). A.R. is supported by a grant from the Acció Instrumental d’Incorporació de Científics i Tecnòlegs (PERIS SLT002/16/00101), Departament de Salut, Generalitat de Catalunya. We want to particularly acknowledge the patients enrolled in this study for their participation and the BioBanc IISPV (B.0000853 + B.0000854) integrated in the Spanish National Biobanks Platform (PT13/0010/0029 & PT13/0010/0062) for its collaboration.
DS RISalud
RD Apr 11, 2025